Key Highlights

  • Five healthcare AI priorities cover research discovery, negative data, patient agents, trusted aggregation and real-world evidence.
  • More than 25 senior executives contributed insights during a two-day healthcare and scientific research summit.
  • Four value-chain stages span early research, clinical development, evidence distribution and patient adoption.
  • Around 93,000 IQVIA employees operate across more than 100 countries supporting healthcare data and clinical services.

John Wiley & Sons, Inc. (NYSE:WLY) and IQVIA Holdings Inc. (NYSE:IQV) released a joint report on Monday examining the use of artificial intelligence across the healthcare value chain, from scientific research to patient treatment.

The report, titled Scientific Discovery & AI: The Science-to-Patient Journey, was developed from discussions held during a two-day summit in May. More than 25 executives from pharmaceutical research, academic institutions, healthcare systems, publishing groups and technology companies participated.

The companies identified five areas with significant potential for healthcare AI adoption. These include using AI to support laboratory target discovery, creating structured databases of failed experiments and introducing patient-facing AI agents to assist people using healthcare systems.

The report also proposed combining academic research with real-world health data to create trusted information resources. A fifth area involves feeding evidence from patient outcomes back into clinical trials, treatment guidelines and early-stage research.

Wiley and IQVIA said AI tools are increasing the speed of molecular analysis and drug-candidate identification. However, the report found that faster discovery does not automatically produce faster clinical development or wider patient access.

The document divides the science-to-patient process into four stages. These cover discovery and early research, clinical development and evidence generation, validation and distribution, and real-world adoption and patient impact.

Participants also identified organisational incentives as a barrier to broader implementation. Existing commercial, academic and healthcare structures may reward separate activities rather than coordinated data sharing across the full research and treatment process.

The report calls for closer links between clinical research, scientific publishing, real-world healthcare information and advanced analytics. It also highlights privacy, regulatory compliance, evidence quality and patient safety as central requirements for healthcare AI systems.

Wiley provides scientific content, research intelligence and education services, while IQVIA supplies clinical research, healthcare data and commercial services to life-sciences companies. The companies said their respective positions connect academic evidence creation with clinical development and real-world use.